InflaRx (IFRX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a treatment targeting SARS-CoV-2-induced acute respiratory distress syndrome in adults. This recommendation, pending European Commission approval, highlights the drug’s potential to improve survival rates in critically ill COVID-19 patients. The development marks a significant milestone for InflaRx, boosting its stock appeal amidst ongoing challenges in COVID-19 treatment.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
